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Abstract  
Introduction: Erlotinib has become an established treatment for patients with non-small cell lung cancer harbouring an 
epidermal growth factor receptor (EGFR) mutation.  Tetracycline antibiotics are commonly prescribed for 
erlotinib-induced acneiform rash.  A rare but morbid complication of tetracycline use is intracranial hypertension, an 
association which has not been reported in the oncology literature. 
Presentation of Case: We report a case of severe intracranial hypertension in a patient with non-small cell lung cancer.  
Risk factors were prolonged tetracycline use and leptomeningeal carcinomatosis.  Initial investigations were unhelpful, 
necessitating a high index of suspicion. 
Conclusion: Tetracycline antibiotics, which are commonly prescribed for erlotinib rash, are an important risk factor for 
intracranial hypertension.  Our patient developed severe vision loss from papilloedema, despite normal neuroimaging 
and relatively low opening pressure on lumbar puncture.  Continuous intracranial pressure monitoring can be a valuable 
investigation in such circumstances. 
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Introduction 
The development of targeted therapies against oncogene-addicted molecular pathways have transformed 
oncology practice.  Advanced non-small cell lung cancers with activating mutations in the epidermal 
growth factor receptor (EGFR) are now treated with EGFR inhibitors such as erlotinib [1, 2]. 
A frequent adverse effect of EGFR inhibitors is development of acneiform rash.  Moderate to severe 
rash occurs in 8 to 12 percent of patients, and treatment guidelines recommend use of tetracycline 
antibiotics [3-5]. 
Intracranial hypertension is an uncommon but serious complication of tetracycline use.  This 
association may not be well recognised by medical oncologists.  A high index of clinical suspicion is 
required as the diagnostic workup can be imprecise and misleading. 
Case presentation 
A 58-year-old Italian male with a seven-pack-year smoking history was diagnosed with metastatic lung 
adenocarcinoma with bone, nodal and lung metastases.  An EGFR mutation (exon 19 deletion) was 
identified.  He commenced erlotinib, an EGFR inhibitor, at the standard dose of 150 mg daily. 
After two months, he developed a grade two acneiform rash affecting his face, upper torso and limbs, 
attributable to erlotinib.  He was prescribed topical hydrocortisone, oral minocycline (50 mg daily) and, 
briefly, topical clindamycin.  After four months, the rash persisted.  Minocycline was uptitrated to 100 
mg daily with good effect.  Serial CT/PET imaging showed complete metabolic response of his lung 
cancer to erlotinib. 
 
 
Figure 1 Bilateral retinal photographs.  Upper images (pre-decompression): severe papilloedema with 
peri-papillary haemorrhages.  Lower images (post-decompression): bilateral optic atrophy. 
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After six months, his condition unexpectedly deteriorated.  He developed morning headaches and 
episodes of disequilibrium, scalp formication, neck tightness and pulsatile tinnitus.  There were 
conscious collapse events.  Neurologic examination was unremarkable, except for fundoscopy which 
revealed severe bilateral papilloedema and peri-papillary haemorrhages (Figure 1). 
Repeated MRI brain scans failed to detect any mass lesion, leptomeningeal enhancement or 
hydrocephalus.  Lumbar puncture (LP) returned a marginally elevated opening pressure of 25 cmH20.  
Malignant cells were present on cytology, consistent with leptomeningeal carcinomatosis. 
Following multidisciplinary review, erlotinib was changed to a pulsed regimen of 1500 mg weekly to 
improve cerebrospinal fluid (CSF) penetration.  Minocycline was ceased.  Oral acetazolamide, 
frusemide and topiramate were unsuccessfully trialled. 
Visual acuity (6/12 bilaterally) and colour vision (3/7 Ishihara plates bilaterally) continued to deteriorate.  
Repeat MRI brain and LP were unchanged, with malignant cells present in the CSF but no abnormality 
seen on MRI.  However, neurosurgical insertion of Codman manometer revealed an actual opening 
pressure of 70 cmH2O, and monitoring pressures approximating 40 cmH2O. 
 
 
Figure 2 Visual field deficits. 
Insertion of a ventriculoperitoneal (VP) shunt immediately improved his symptoms of intracranial 
hypertension.  However, post-papilloedema optic nerve atrophy resulted in a final visual acuity of 6/36 
Ivy Union Publishing | http: //www.ivyunion.org August 1, 2015 | Volume 3, Issue 3 
Sim HW et al. American Journal of Cancer Case Reports 2015, 3:148-153 
6
Page 4 of 6 
OS and 6/9 OD with extensive visual field loss (Figure 2).  He remained otherwise well but later 
succumbed to progressive cancer two years four months post shunt insertion. 
Discussion 
Intracranial hypertension in our patient was a consequence of prolonged minocycline use and/or 
leptomeningeal carcinomatosis. 
Tetracycline antibiotics have been reported in case series to cause intracranial hypertension [6-13].  A 
postulated mechanism is interference with energy dependent uptake pathways in the arachnoid 
granulations, restricting CSF absorption [7]. Some individuals may be genetically predisposed to this 
effect [10].  Despite their widespread use for erlotinib rash, to our knowledge, this is the first report of 
tetracycline-related intracranial hypertension when used for this indication. 
Most patients experience improvement after drug cessation.  However, despite the short half-life of 
these agents, recovery often takes several months and may be incomplete [11, 13].  Prompt recognition 
and aggressive management is therefore crucial.  Supportive therapies to alleviate intracranial 
hypertension include carbonic anhydrase inhibitors, loop diuretics and topiramate, which act by reducing 
CSF production rate.  Neurosurgical decompression is necessary in fulminant or refractory cases [14, 
15]. 
Opening pressures on LP in our patient were only slightly elevated, however central monitoring 
demonstrated severe intracranial hypertension.  LP opening pressures are generally representative of 
pressure in all CSF spaces [16].  However, this measure can be notoriously unreliable, especially in the 
setting of altered CSF dynamics [17, 18].  Furthermore, CSF pressures are dynamic and single readings 
may miss elevations if performed between pressure waves [19, 20]. 
In this case, vision loss progressed despite misleadingly normal investigations, emphasising the 
importance of papilloedema as a clinical sign and an indication of threat to vision. 
Conclusion 
Patients with lung cancer being treated for rash with prolonged courses of tetracycline antibiotics are at 
increased risk of intracranial hypertension, which can be life- and sight-threatening.  We highlight the 
importance of papilloedema as a clinical sign, and the role of continuous intracranial pressure monitoring 
in cases with discordant clinical findings and investigations. 
Consent 
The patient was deceased at the time of manuscript preparation.  As per correspondence with the 
editorial board, the requirement for consent has been waived. 
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